Testing new antiviral agents against respiratory viruses like SARS-CoV-2.
Official title: Task B25: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses, SARS-CoV-2
Funded at Utah State University · NIH-11202355 · Data updated 2026-11-12
This study is looking at new medicines that might help fight respiratory viruses like COVID-19, and it could lead to better treatments for patients dealing with these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Utah State University NIH-funded |
| Lab location | 1 site (Logan, United States) |
| Project start | September 23, 2024 |
| Project end | September 22, 2025 |
| Funding year | 2024 |
| Award (this year) | $206,532 |
| NIH project number | 75N93019D00021-0-759302400002-2 |
| Project ID | NIH-11202355 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of severe respiratory viral infections, including those with underlying health conditions.
✕Less likely to help
Patients who are not at risk for respiratory viral infections or those who have already recovered from COVID-19 may not receive benefit from this research.
What this research studies
This research focuses on evaluating the effectiveness of potential antiviral agents against respiratory viruses, specifically SARS-CoV-2, through laboratory testing. It involves maintaining viral stocks and cell lines necessary for growing the viruses and developing assays to measure the antiviral activity. Patients may benefit from this research as it aims to identify new treatments that could help combat COVID-19 and similar respiratory infections.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antiviral treatments for COVID-19 and other respiratory viruses.
How similar studies have gone: Other research has shown success in developing antiviral agents against respiratory viruses, indicating that this approach has potential.
Where this research is happening
-
Utah State University
Logan, United States Active
Researchers
- Principal investigator: Hurst, Brett — Utah State University
- Study coordinator: Hurst, Brett
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.